Streetbeat News

Equity Actions

ARCT

Arcturus Therapeutics (NASDAQ:ARCT) has seen a variety of analyst ratings over the past three months, with a recent positive shift in sentiment. Four analysts have provided ratings, with the latest 12-month price targets showing an average of $63.25, up 14.31% from the previous $55.33. The company's financial performance has been strong, with significant revenue growth and above-average financial metrics compared to the industry. Arcturus focuses on RNA medicines for rare diseases, with a notable pipeline including LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 12:01 pm

CGC

Canopy Growth Corporation (CGC) announced a special resolution for shareholders to vote on creating an unlimited number of new non-voting, non-participating exchangeable shares. This amendment also includes a conversion feature allowing common shares to be converted into exchangeable shares and vice versa. The vote is scheduled for April 12, 2024. If approved, this will enable shareholders to convert their shares post the effective time of the amendment. Notices of Conversion will be available on the company's website and filed with the SEC and Canadian regulators.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:59 am

IVCB

Investcorp Europe Acquisition Corp I (IVCB) has amended its Business Combination Agreement (BCA) following the divestiture of OpSec Security, which is to be acquired by Crane NXT for $270 million. The amendment involves Zacco becoming a stand-alone business. The Board of Directors of Investcorp Europe is currently evaluating the amended BCA to consider a merger with Zacco and intends to seek a deadline extension to complete the initial business combination.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:42 am

LXEO

Lexeo Therapeutics has successfully completed an oversubscribed $95M equity financing round, selling 6.278 million shares at $15.13 each to institutional and healthcare accredited investors in a private placement.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:39 am

LXRX

Lexicon Pharmaceuticals' shares surged after the company announced plans to resubmit its Sotagliflozin NDA for Type 1 diabetes based on FDA feedback. Furthermore, Lexicon revealed a securities purchase agreement anticipated to generate approximately $250 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:22 am

LXRX

Lexicon Pharmaceuticals, Inc. has announced an oversubscribed $250 million private placement of equity securities. This significant capital raise indicates strong investor interest and confidence in Lexicon's future prospects.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:08 am

EOLS

Evolus announced the pricing of a $50M offering of common stock, with an option for underwriters to purchase up to an additional 533,100 shares. The offering is expected to close around March 13, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:03 am

NFG

National Fuel (NFG) has announced a new share repurchase program, authorizing the repurchase of up to $200M of its outstanding common stock with a target completion by the end of fiscal 2025.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:52 am

CHH

Choice Hotels' board has approved an increase in the number of shares authorized for repurchase by 5 million shares, bringing the total authorization to approximately 6.8 million shares.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:35 am

CHH

WH

Wyndham is advocating for its shareholders to back its eight director nominees, rejecting the nominees from Choice Hotels. Wyndham believes its strategy will deliver greater shareholder value than the offer from Choice Hotels, which it considers inadequate and uncertain.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:03 am